ARWR - Arrowhead Pharmaceuticals, Inc.
46.94 -0.64 (-1.35%)
Pre-Market: 9:04AM EST
| Previous Close | 47.59 |
| Open | 47.59 |
| Bid | 47.14 x 2200 |
| Ask | 47.20 x 2200 |
| Day's Range | 47.45 - 49.31 |
| 52 Week Range | 12.56 - 73.72 |
| Volume | 1,835,260 |
| Avg. Volume | 2,382,919 |
| Market Cap | 4.773B |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | 68.96 |
| EPS (TTM) | 0.69 |
| Earnings Date | Feb 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.63 |
- Investor's Business Daily
Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?
Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study.
- Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
- Investor's Business Daily
Why This Top-Notch Biotech Stock Just Plunged By Double Digits
Shares of highly rated biotech company Arrowhead Pharmaceuticals crashed to a two-month low Tuesday after an analyst initiated coverage of ARWR stock with an underperform rating.
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR).
- Investor's Business Daily
These Four Stocks Are In Buy Range Before Key Healthcare Conference
Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference. Arrowhead Pharma stock is testing key support.
- InvestorPlace
3 Biotech Stocks to Bank on for Buyouts in 2020
Heading into the new year, only one word matters for the biotech stocks: buyout.Already, we've seen a fury of activity this past year, as many of the larger pharmaceutical and biotech giants look to plug holes in their aging pipelines. This activity accelerated at the end of the end, with Novartis (NYSE:NVS), Merck (NYSE:MRK) and Sanofi (NASDAQ:SNY) all making big blockbuster buys over the last month or so.And, the buys could continue into the new year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor one thing, many of the big biotech stocks are flushed with cash. Thanks to the tax cuts of 2017, repatriation of cash and continued sales of blockbuster drugs, many of the biggest biotech stocks are holding billions on their balance sheets. Meanwhile, pipelines and approvals of new drugs are starting to dry up. According to investment bank JPMorgan Chase (NYSE:JPM), over the last 20 years, the FDA has only approved an average of between 20 and 25 new drugs per year. Most of those approvals have come from advanced drugs, new cancer fighters and a hefty dose of biologics.With the need to fill pipelines and replace aging blockbusters, the major biotech stocks are in a bind. And that means buying their way out of these issues. * The Top 15 Stocks to Buy in 2020 For investors, this poises an interesting scenario. Plenty of gains can be had betting on the right biotech stock with a promising pipeline as the bigger fish start spending their cash. However, which biotech stocks have the promise?Here are three biotech stocks that make for great buyout targets. Biotech Stocks That Are Buyout Targets: Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock It's no secret that gene therapy has quickly become all the rage, with pharmaceutical firms trying to tackle rare and orphan diseases. And while there are a ton of new technologies that fall under this umbrella, RNA interference (RNAi) has the potential to be a real game changer.Basically, it's a mechanism that uses a "gene's own DNA sequence of gene to turn it off." With Novartis spending nearly $10 billion on RNAi buyouts in recent months, Arrowhead Pharmaceuticals (NASDAQ:ARWR) could be an intriguing stock to look at it.ARWR's sole specialty is RNAi drugs and features a big pipeline of therapies in various stages of development. These drugs include tackling aliments like liver disease, Cystic Fibrosis and cancerous tumors. So far, the biotech has been pretty successful at navigating the various phases of clinical trials. Data from many of its late-stage drugs seem very promising.However, the real reason to be excited that ARWR could be bought out is that it already counts a very deep-pocketed biotech among its development partners. Arrowhead has already cut deals with Johnson & Johnson (NYSE:JNJ) for development of treatment for chronic hepatitis B infections. The deal provides ARWR with plenty of upfront cash, development and milestone rights. However, given the rush to buyout RNAi providers, JNJ has every reason to consider snagging the firm outright.Now, Arrowhead isn't unknown at this point. In fact, the stock has surged over the last year -- especially since October. Some of that was do to the NVS buyouts in the sector. But, a lot of it was do to ARWR's own wins and progress. But, with plenty of potential and market cap of just $6 billion, Arrowhead could provide more gains in the year ahead -- buyout or not. Amarin (AMRN)Source: Shutterstock A lot has been written about Amarin (NASDAQ:AMRN). The biotech stock has been a roller coaster the last few years, going from obscurity to being on hot lists. The reason comes down to its only medicine -Vascepa.Vascepa is really just a fish oil pill. But man, is it good. Data for the drug was stellar, with patients experiencing a 20% less chance of cardiovascular death, 31% less heart attacks and 28% less strokes. All in all, Vascepa was able to reduce cardiovascular risk by 25%. With its big cache of data and FDA approval, AMRN now has a blockbuster on its hands. Patients facing cardiovascular events who are already on statins now have another line of defense to fight. With that, AMRN now predicts that it'll be able to accumulate $650 to $700 million in sales this year.So, why buyout potential? That's an easy source of bolt-on revenue with some decent growth prospects.Cardiovascular disease remains a huge threat that only continues to get worse as diet and genetics play an increasing role. Vascepa has the potential to be the next Lipitor in that fight. And that blockbuster potential makes it a great add-on for drug companies with big cardiovascular portfolios. With a market cap of only $7 billion, Amarin is a pretty easy pill to swallow for a larger biotech stock looking to boost its sagging growth potential. * 3 Oil Stocks That Are Worth Looking Into Now In the end, Vascepa could be a blockbuster and that could lead to a sale of ARMN stock. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Non-alcoholic SteatoHepatitis (NASH) remains a tough nut to crack. The progressive liver disease can destroy the organ, and is projected to become the leading cause of all liver transplants this year. For nations with fatty diets, prevalence of NASH is estimated to be as much as 20% of the total population. The problem is that most potential treatments for the disease have fallen flat.And, that could make Intercept Pharmaceuticals (NASDAQ:ICPT) the only boat in the sea.Intercept's drug Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC). PBC is very similar to NASH. This allowed ICPT to pivot the medicine and results were pretty great. So great, that ICPT recently submitted the drug for review with the FDA.Perhaps even better is that the agency granted Intercept priority review for the drug. That could lead to quicker approval time and reduce the headaches ICPT needs to get the therapy out to market.Given the potential size of NASH and the need for the drug, ICPT could be looking at a major blockbuster on it hands. And as the only man standing in the sector, that could lead to plenty of buyout activity for the stock. This is especially true as shares of the firm have slipped over the last year, but gained traction in October. With a market cap of about $4 billion, Intercept is a very digestible for many other biotech stocks.In the end, ICPT is sitting right in the sweet spot for mergers and acquisitions activity. With strong growth potential, first-mover status and a low market cap all being factors. At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post 3 Biotech Stocks to Bank on for Buyouts in 2020 appeared first on InvestorPlace.
- Business Wire
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Arrowhead hires James Hassard as Chief Commercial Officer
- Investor's Business Daily
Biotech Stocks Are On Fire — Who's Leading The Profit Pack For 2020?
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
- Investor's Business Daily
Best Stocks 2019: Innovation, As Usual, Wins The Day — Or Even The Year
Throughout the year's list of the best stocks of 2019, there is an undercurrent of groundbreaking products and services that shape the way we live.
- Zacks
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
Style Box ETF report for FNY
- MarketWatch
What was the top stock of 2019? And should it be in your retirement account?
MARK HULBERT How many of you owned stock of Arrowhead Pharmaceuticals at the beginning of this year? I ask because it’s the best-performing stock of 2019 (through Dec. 3) out of the stocks in the S&P 1500 index (XX:SP1500) sporting a gain of over 450% (according to FactSet).
- TheStreet.com
Arrowhead Pharma Investors Should Aim for Taking Profits
When speculative stocks make big moves to the upside, the prudent thing to do is take some profits, Jim Cramer reminded viewers during Friday night's "Mad Money" program. Case in point: Arrowhead Pharmaceuticals which is up 411% in 2019 and 133% in just the past six months. Cramer said he's still a big fan of Arrowhead and its technology that silences the genes that cause disease.
- Zacks
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
- Business Wire
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT
- Thomson Reuters StreetEvents
Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT
Q4 2019 Arrowhead Pharmaceuticals Inc Earnings Call
- Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
- Business Wire
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
Arrowhead files CTA for Phase 1 clinical trial of ARO-HSD, the company’s RNAi therapeutic for alcohol and nonalcohol related liver diseases like NASH
- PR Newswire
Live Nation Entertainment, Zebra Technologies, STERIS Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P; Dow Jones Indices will make the following index adjustments to the S&P; 500, S&P; MidCap 400 and S&P; SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, December 23 to coincide with the December rebalance.
- Business Wire
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
Arrowhead Pharmaceuticals appointed veteran pharmaceutical industry executive Marianne De Backer, Ph.D., as an independent director of the company
- Insider Monkey
Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
- Business Wire
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
- Business Wire
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
- Business Wire
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Arrowhead Pharmaceuticals Inc. (ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts. The offering is expected to close on or about December 6, 2019, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters of the offering a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less the underwriting discount.
- Investopedia
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
